Drug updated on 9/27/2024
| Dosage Form | Injection (subcutaneous; 250 mg/2 mL in a single-dose prefilled pen, 250 mg/2 mL in a single-dose prefilled syringe with needle shield) |
| Drug Class | interleukin-13 antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.
Latest News
Summary
- This summary is based on the review of seven systematic review(s)/meta-analysis(es). [1-8]
- Lebrikizumab demonstrated significant improvement in EASI75 at Week 16 with a risk ratio (RR) of 2.62 compared to placebo, with greater improvement in EASI (MD -20.37) and DLQI (MD -14.49) compared to placebo.
- Among systemic treatments for atopic dermatitis, lebrikizumab 250 mg fortnightly showed the highest improvement in peak pruritus scores (LSM -64.90) but had similar short-term effectiveness to dupilumab.
- High-dose upadacitinib and abrocitinib had higher efficacy in EASI-50, EASI-75, and EASI-90 outcomes compared to lebrikizumab.
- Lebrikizumab was not significantly associated with serious adverse events (SAEs), non-serious adverse events (NSAEs), or mortality compared to placebo.
- There was an increased risk of conjunctivitis reported with lebrikizumab and tralokinumab.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| EBGLYSS (lebrikizumab-lbkz) Prescribing Information. | 2024 | Eli Lilly and Company, Indianapolis, IN |